Seegnal Reports Second Quarter 2026 Financial Results and Provides Business Update

Expanded Israeli Hospital Footprint with Five-Year Deployment at Nazareth Hospital EMMS

Second Quarter Revenue Increased 15% to $351,000 and First Half Revenue Increased 16% to $706,000

CALGARY, Alberta, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a developer of innovative healthcare technology focused on mitigating medication risks, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update.

Recent Business Highlights

• Graduated from AARP Accelerator: In August 2026, Seegnal completed the eight-week Summer 2026 cohort of the AgeTech Collaborative™ from AARP Accelerator Program, as part of the Company’s U.S. market development activities. AARP is the largest nonprofit, nonpartisan organization in the United States dedicated to empowering people 50 and older to choose how to live as they age.
• Deepened Footprint in the Israeli Healthcare System: Seegnal continued to scale across the Israeli healthcare system, where its platform is used daily by more than 15,000 clinicians. In June 2026, the Company announced that it had signed a five-year agreement to deploy across Nazareth Hospital EMMS (approximately 424 physicians and nurses), adding to the Company’s existing multi-year deployment at Tel Aviv Sourasky Medical Center. In April 2026, its Israeli subsidiary, Seegnal eHealth Ltd., received the Gold Mark from the Standards Institution of Israel.
• Non-Brokered Private Placement: On June 2, 2026, the Company announced a non-brokered private placement of up to C$1,300,000, which it subsequently extended until August 31, 2026 pursuant to a news release dated July 21, 2026, and which was further extended until September 30, 2026 pursuant to a news release dated August 26, 2026 (the “Extended Offering”). Additionally, the Extended Offering was upsized to up to C$1,850,000, comprising up to 6,607,143 units at C$0.28 per unit (each unit consisting of one common share and one common share purchase warrant exercisable at C$0.50 for 36 months). The Extended Offering is expected to close on or before September 30, 2026.

Financial Results for the Three and Six Months Ended June 30, 2026

All figures are in U.S. dollars unless otherwise noted. The following disclosure does not constitute full disclosure of the Company’s financial and operational condition and is qualified by, and should be read in conjunction with, the Company’s Management’s Discussion and Analysis for the three and six months ended June 30, 2026 (the “MD&A”) and corresponding financial statements, available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

• Revenue was $351,000 for the three months ended June 30, 2026, an increase of 15% compared to $306,000 for the same period in 2025. For the six months ended June 30, 2026, revenue was $706,000, an increase of 16% compared to $609,000 for the same period in 2025.
• Cost of revenues was $366,000 for the three months ended June 30, 2026, compared to $261,000 for the same period in 2025, resulting in a gross loss of $15,000 compared to a gross profit of $45,000. For the six months ended June 30, 2026, the Company reported a gross loss of $32,000 compared to a gross profit of $34,000 for the same period in 2025.
• Research and development costs were $293,000 for the three months ended June 30, 2026, compared to $131,000 for the same period in 2025, and $530,000 for the six months ended June 30, 2026, compared to $249,000 for the same period in 2025.
• Sales and marketing expenses were $73,000 for the three months ended June 30, 2026, compared to $167,000 for the same period in 2025, and $212,000 for the six months ended June 30, 2026, compared to $315,000 for the same period in 2025.
• General and administration costs were $271,000 for the three months ended June 30, 2026, compared to $335,000 for the same period in 2025, and $860,000 for the six months ended June 30, 2026, compared to $618,000 for the same period in 2025.
• Net loss for the three months ended June 30, 2026 was $765,000, or $(0.02) per share, a decrease of approximately 11% compared to a net loss of $857,000, or $(0.13) per share, for the same period in 2025. For the six months ended June 30, 2026, net loss was $1,813,000, or $(0.04) per share, compared to $1,650,000, or $(0.25) per share, for the same period in 2025.
• Cash Position and Financing: As of June 30, 2026, the Company had cash of $181,000 (December 31, 2025: $678,000) and trade receivables of $237,000. The Company continues to report operating losses and negative cash flow from operations. As further described in the MD&A and the notes to the Company’s financial statements, the continuance of the Company’s operations is subject to continued financing from shareholders and other investors, which represents a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. In June 2026, the Company announced a non-brokered private placement, which was subsequently extended in July and August 2026 to up to C$1,850,000, expected to close on or before September 30, 2026.

About Seegnal
Seegnal Inc. (TSXV: SEGN) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company’s SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age, and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing, and advance a more personalized standard of patient care. Seegnal’s technology is deployed across healthcare settings and is used by more than 15,000 clinicians in daily practice. For additional Company information, please visit https://investors.seegnal.com/ and follow us on LinkedIn.

Forward-Looking Information
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements regarding the Company’s revenue growth and commercial expansion; the adoption, deployment and integration of the Seegnal platform, including at Nazareth Hospital EMMS and other healthcare institutions; the Company’s entry into and expansion within the U.S. healthcare market, including the conversion of its letter of intent and pilot program into commercial arrangements; the Company’s ability to complete the Extended Offering; the completion, timing and terms of the Company’s non-brokered private placement; the Company’s liquidity, funding initiatives and ability to continue as a going concern; and management’s expectations regarding future performance. Forward-looking information is based on assumptions and is subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the Company’s ability to obtain financing on acceptable terms or at all, its history of losses and going concern, the early stage of its U.S. market entry, reliance on key customers and healthcare institutions, currency fluctuations, and the geopolitical situation in Israel. For a more complete discussion of the risks and uncertainties applicable to the Company, please refer to the risk factors described in the Company’s most recently filed annual management’s discussion and analysis, available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The forward-looking information in this news release is made as of the date hereof, and the Company undertakes no obligation to update it except as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Seegnal Inc.
Elad Bibi-Aviv, Chief Executive Officer
+1 (929) 248 4652

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
seegnal@arxhq.com